Compare Globus Medical Inc. Class A Common Stock (GMED) vs US Bancorp (USB) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Globus Medical Inc. Class A Common Stock vs US Bancorp — how do they compare? Globus Medical Inc. Class A Common Stock trades at $76.58 (market cap $10.25B), while US Bancorp trades at $56.26 (market cap $88.64B). The key difference: US Bancorp is far larger — about 8.6× Globus Medical Inc. Class A Common Stock's market cap, and US Bancorp pays a 3.8% dividend while Globus Medical Inc. Class A Common Stock pays none. Which is the better fit depends on your goals — on Pluang, investors hold Globus Medical Inc. Class A Common Stock for 0 Days and US Bancorp for 98 Days on average.
| GMED | USB | |
|---|---|---|
Market Cap | $10.25B | $88.64B |
Volume | 1,108,124 | 8,200,583 |
Sector | Health | Financials |
52-Week High | $96.82 | $65.42 |
52-Week Low | $58.33 | $45.47 |
Typical Hold Time | 0 Days | 98 Days |
Enterprise Value | $9.76B | $118.14B |
Dividend Yield | — | 3.8% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Globus Medical (GMED) trades at $76.32, showing minimal daily movement with a 0.1% gain. The stock demonstrates strong fundamental performance with consistent earnings beats in recent quarters and robust profitability metrics including 68.55% gross margins and 17.03% net income margins. Technical indicators suggest neutral positioning near key support at $73 with resistance at $74. Recent developments include new product showcases at industry conferences and upcoming Q3 earnings release.
GMED presents a compelling investment case with strong analyst support (72% buy rating) and 25% upside to consensus target of $95.13. The company maintains solid revenue growth trajectory and debt-free balance sheet, though investors should monitor competitive pressures in medical devices and potential margin compression as revenue scales. Near-term catalysts include Q3 earnings results expected November 5, 2026.
U.S. Bancorp (USB) trades at $56.89, down 0.92% with bearish technical signals but strong fundamentals including consistent earnings beats and a 27.61% net margin. The stock shows a P/E of 11.36 and ROE of 13.53%, with analyst consensus at Buy (51%) and a $69.94 price target. Recent news highlights dividend increases and strong Q3 expectations for net interest income and fee revenues.
Outlook remains positive based on valuation and earnings momentum, though risks include regulatory changes and interest rate sensitivity. The 3.8% dividend hike to $0.54 signals management confidence, but investors should monitor net cash flow trends and competitive pressures in regional banking.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
No sentiment data available yet.
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Globus Medical Inc. Class A Common Stock
Globus Medical, Inc. develops and manufactures medical devices for treating musculoskeletal disorders, including spine, orthopedic trauma, and neurosurgical products. It operates in US and internationally, serving surgeons and healthcare providers.
Read more on GMED →About US Bancorp
As a diversified financial-services provider, U.S. Bancorp is one of the nation's largest regional banks, with branches in well over 20 states, primarily in the Western and Midwestern United States. The bank offers many services, including retail banking, commercial banking, trust and wealth services, credit cards, mortgages, and other payments capabilities.
Read more on USB →
